 Kevin Ginn
Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 10 | 2023 | 44 | 2.350 |
Why?
| | Medulloblastoma | 4 | 2023 | 9 | 1.220 |
Why?
| | Glioma | 3 | 2023 | 26 | 0.670 |
Why?
| | ral GTP-Binding Proteins | 1 | 2016 | 1 | 0.590 |
Why?
| | Cerebellum | 1 | 2016 | 13 | 0.580 |
Why?
| | Neuroblastoma | 2 | 2024 | 10 | 0.480 |
Why?
| | Cerebellar Neoplasms | 2 | 2023 | 4 | 0.460 |
Why?
| | Mutation | 6 | 2023 | 194 | 0.410 |
Why?
| | Craniopharyngioma | 2 | 2020 | 2 | 0.390 |
Why?
| | Humans | 16 | 2024 | 6599 | 0.360 |
Why?
| | Child | 10 | 2024 | 3146 | 0.280 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 71 | 0.240 |
Why?
| | Glioblastoma | 1 | 2023 | 17 | 0.230 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2022 | 50 | 0.230 |
Why?
| | Central Nervous System Neoplasms | 1 | 2023 | 5 | 0.230 |
Why?
| | Craniospinal Irradiation | 1 | 2022 | 1 | 0.230 |
Why?
| | Adrenal Insufficiency | 1 | 2022 | 4 | 0.210 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2021 | 1 | 0.210 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 2 | 0.210 |
Why?
| | Spinal Cord Neoplasms | 1 | 2021 | 3 | 0.210 |
Why?
| | Male | 6 | 2021 | 3197 | 0.200 |
Why?
| | Tissue Array Analysis | 1 | 2020 | 5 | 0.200 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 4 | 0.190 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 11 | 0.190 |
Why?
| | Signal Transduction | 2 | 2023 | 107 | 0.190 |
Why?
| | Pituitary Neoplasms | 1 | 2020 | 1 | 0.190 |
Why?
| | Mice | 2 | 2023 | 290 | 0.190 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 116 | 0.180 |
Why?
| | Syndactyly | 1 | 2019 | 4 | 0.180 |
Why?
| | Skin Abnormalities | 1 | 2019 | 3 | 0.180 |
Why?
| | Craniofacial Abnormalities | 1 | 2019 | 10 | 0.180 |
Why?
| | Transcriptome | 1 | 2020 | 50 | 0.180 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 94 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 114 | 0.180 |
Why?
| | Intestines | 1 | 2019 | 26 | 0.180 |
Why?
| | Animals | 2 | 2023 | 563 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2024 | 33 | 0.170 |
Why?
| | Infant | 5 | 2023 | 1396 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 340 | 0.170 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 215 | 0.160 |
Why?
| | Female | 4 | 2021 | 3436 | 0.150 |
Why?
| | Transduction, Genetic | 1 | 2016 | 3 | 0.150 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2016 | 3 | 0.150 |
Why?
| | Aurora Kinase A | 1 | 2016 | 3 | 0.150 |
Why?
| | Mice, Nude | 1 | 2016 | 10 | 0.150 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 19 | 0.150 |
Why?
| | Gene Silencing | 1 | 2016 | 13 | 0.150 |
Why?
| | RNA, Small Interfering | 1 | 2016 | 19 | 0.150 |
Why?
| | Fetus | 1 | 2016 | 16 | 0.140 |
Why?
| | Cell Proliferation | 1 | 2016 | 55 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 51 | 0.140 |
Why?
| | Infant, Newborn | 4 | 2021 | 790 | 0.140 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 87 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 92 | 0.140 |
Why?
| | Protoporphyria, Erythropoietic | 1 | 2015 | 1 | 0.130 |
Why?
| | Chromosomes, Human, X | 1 | 2015 | 5 | 0.130 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 9 | 0.130 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2015 | 4 | 0.130 |
Why?
| | Young Adult | 3 | 2023 | 652 | 0.130 |
Why?
| | Choroid Plexus Neoplasms | 1 | 2015 | 1 | 0.130 |
Why?
| | Carcinoma | 1 | 2015 | 6 | 0.130 |
Why?
| | Primary Health Care | 1 | 2014 | 44 | 0.130 |
Why?
| | Child, Preschool | 4 | 2022 | 1459 | 0.120 |
Why?
| | Adult | 3 | 2023 | 1233 | 0.120 |
Why?
| | Neoplasms | 1 | 2014 | 119 | 0.110 |
Why?
| | Cohort Studies | 2 | 2022 | 264 | 0.100 |
Why?
| | Cyclophosphamide | 2 | 2023 | 8 | 0.090 |
Why?
| | Algorithms | 2 | 2020 | 103 | 0.090 |
Why?
| | Prospective Studies | 2 | 2022 | 508 | 0.080 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 5 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2023 | 17 | 0.060 |
Why?
| | Nifurtimox | 1 | 2023 | 1 | 0.060 |
Why?
| | Topotecan | 1 | 2023 | 1 | 0.060 |
Why?
| | World Health Organization | 1 | 2023 | 5 | 0.060 |
Why?
| | Inhibitor of Differentiation Protein 1 | 1 | 2023 | 2 | 0.060 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 5 | 0.060 |
Why?
| | Calcium-Binding Proteins | 1 | 2023 | 9 | 0.060 |
Why?
| | Histones | 1 | 2023 | 15 | 0.060 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 13 | 0.060 |
Why?
| | Chronic Disease | 1 | 2022 | 103 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 3 | 0.050 |
Why?
| | Brain | 1 | 2023 | 74 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2022 | 7 | 0.050 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 7 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2022 | 29 | 0.050 |
Why?
| | Data Accuracy | 1 | 2020 | 6 | 0.050 |
Why?
| | Preoperative Period | 1 | 2020 | 5 | 0.050 |
Why?
| | Models, Theoretical | 1 | 2020 | 10 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2020 | 31 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2020 | 38 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 145 | 0.050 |
Why?
| | Computational Biology | 1 | 2020 | 40 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 109 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2023 | 1251 | 0.040 |
Why?
| | Middle Aged | 1 | 2020 | 648 | 0.040 |
Why?
| | 5-Aminolevulinate Synthetase | 1 | 2015 | 1 | 0.030 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 4 | 0.030 |
Why?
| | Liver Function Tests | 1 | 2015 | 3 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2015 | 20 | 0.030 |
Why?
| | Genetic Linkage | 1 | 2015 | 12 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 17 | 0.030 |
Why?
| | International Agencies | 1 | 2015 | 1 | 0.030 |
Why?
| | Cranial Irradiation | 1 | 2015 | 1 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2015 | 1 | 0.030 |
Why?
| | Carboplatin | 1 | 2015 | 5 | 0.030 |
Why?
| | Vincristine | 1 | 2015 | 8 | 0.030 |
Why?
| | Cisplatin | 1 | 2015 | 8 | 0.030 |
Why?
| | Etoposide | 1 | 2015 | 11 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2015 | 31 | 0.030 |
Why?
| | Biopsy | 1 | 2015 | 56 | 0.030 |
Why?
| | Survival Rate | 1 | 2015 | 84 | 0.030 |
Why?
| | Emergencies | 1 | 2014 | 11 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 74 | 0.030 |
Why?
| | Prognosis | 1 | 2015 | 209 | 0.030 |
Why?
| | Liver | 1 | 2015 | 119 | 0.030 |
Why?
| | Adolescent | 1 | 2020 | 2087 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2015 | 315 | 0.030 |
Why?
| | Risk Factors | 1 | 2014 | 460 | 0.030 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|